In an observational study that included data from 193,072 atrial fibrillation patients treated with DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban), the various DOACs were associated with similar benefits, but apixaban was correlated with the lowest and dabigatran with the second-lowest risks of major and clinically relevant non-major bleeding events
Issue Section Original Articles
The primary diagnosis code should reflect the clinical manifestation (e.g., K85.3 for drug-induced pancreatitis), followed by an external cause code from the Y40Y59 range to indicate the medication involved
People often notice the biggest benefit in areas like the forehead, crows-feet region, and around the mouth, where daily emotions create the strongest patterns
Legal Implications As the MDL gains traction, legal experts anticipate a thorough examination of the evidence surrounding the alleged failure of manufacturers to disclose adverse gastric effects